Heart Septal Defects, Ventricular
13
0
0
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.7%
1 terminated out of 13 trials
90.0%
+3.5% vs benchmark
15%
2 trials in Phase 3/4
11%
1 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (13)
Aberrations in Carnitine Homeostasis in Congenital Heart Disease With Increased Pulmonary Blood Flow
Closure of Muscular Ventricular Septal Defects With The AMPLATZER™ Muscular VSD Occluder
Safety and Effectiveness of the Nit-Occlud® Lê VSD Spiral Coil System
Molecular Genetic Epidemiology of Endocardial Cushion Defects - SCOR in Pediatric Cardiovascular Disease
Infant Heart Surgery: Central Nervous System Sequelae of Circulatory Arrest
Molecular Genetic Epidemiology of Three Cardiac Defects -SCOR in Pediatric Cardiovascular Disease
Reproduction and Survival After Cardiac Defect Repair
A Randomized Controlled Trial:Treatments on Infundibular Ventricular Septal Defect
Right Bundle Branch Block After Surgical Closure of Ventricular Septal Defect
Angiotensin Converting Enzyme Inhibition in Children With Mitral Regurgitation
Hypertonic Saline Dextran in Pediatric Cardiac Surgery
Aortic Regurgitation After Surgical Repair of Outlet-Type Ventricular Septal Defect
Study of Energy Expenditure in Infants With Ventricular Septal Defects